Article

Robert W. Dubois, MD, PhD, Describes the Initial Expectations of Accountable Care Organizations

Conference|AMCP: The Academy of Managed Care Pharmacy

Robert W. Dubois, MD, PhD, the chief science officer of the National Pharmaceutical Council discusses the initial expectations of implementing accountable care organizations (ACOs) and how those expectations have evolved over time.

Robert W. Dubois, MD, PhD, the chief science officer of the National Pharmaceutical Council discusses the initial expectations of implementing accountable care organizations (ACOs) and how those expectations have evolved over time.

This video was taken at the Academy of Managed Care Pharmacy's 25th Annual Meeting & Expo in San Diego, CA, on April 4, 2013.

Related Videos
Milind Desai, MD
Masanori Aikawa, MD
Neil Goldfarb, GPBCH
Mabel Mardones, MD.
Mei Wei, MD, an oncologist specializing in breast cancer at Huntsman Cancer Institute at the University of Utah.
Alexander Mathioudakis, MD, PhD, clinical lecturer in respiratory medicine at The University of Manchester
dr carol regueiro
dr carol regueiro
dr carol regueiro
Screenshot of Susan Wescott, RPh, MBA
Related Content
Semaglutide injectors. | Image Credit :Andreas Prott- stock.adobe.com
November 21st 2024

Semaglutide Eligibility Expands to Over Half of US Adults

Cameron Santoro
Over half of the US adult population may benefit from semaglutide, a drug primarily used for weight loss and diabetes, although concerns about access and cost persist, especially considering its potential for wider health applications.
Managed Care Cast logo
April 25th 2024

Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic

Brooke McCormick
On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Blood test | Image: Edward Jenner for Pexels
November 18th 2024

KRAKEN: Oral Muvalaplin Safely Lowers Lp(a) in Early-Stage Trial

Mary Caffrey
Results bring more competition to treat this genetically driven target for cardiovascular risk.
Oncololgy Onward graphic with Dr Bekelman
December 19th 2023

Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman

Maggie L. Shaw
Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Entresto packaging | Image credit: Novartis
November 18th 2024

Cardiomyopathy Risk Plummets When Sacubitril/Valsartan Taken With Chemo

Mary Caffrey
The SARAH trial was limited to high-risk patients, which the lead investigator said prevented unnecessary exposure to adverse events in patients less at risk of cardiomyopathy.
Kerendia press photo | Image credit: Bayer
November 18th 2024

Benefits of Finerenone Similar in Women and Men, Analysis Finds

Mary Caffrey
Follow-up results for the FINEARTS-HF trial focused on specific results for women and men, hyperkalemia risk, and an analysis of the elements of its composite end point.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo